Search research articles
Contact Us
Filters
Showing results (111-120 of 148) with videos related to
Page
of 15
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 26, 2017
De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR- phase II trial: efficacy, safety, and predictive markers for 12 weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab ± weekly paclitaxel
U A Nitz, O Gluz, M Christgen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 6, 2024
A pooled analysis of trastuzumab deruxtecan in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer with brain metastases
F André, J Cortés, G Curigliano, et al.
ESMO Open
|
November 28, 2021
Prognostic relevance of the HER2 status of circulating tumor cells in metastatic breast cancer patients screened for participation in the DETECT study program
V Müller, M Banys-Paluchowski, T W P Friedl, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 23, 2020
ESO-ESMO 4th International Consensus Guidelines for Breast Cancer in Young Women (BCY4)
S Paluch-Shimon, F Cardoso, A H Partridge, et al.
ESMO Open
|
March 5, 2024
Prognostic value of HER2DX in early-stage HER2-positive breast cancer: a comprehensive analysis of 757 patients in the Sweden Cancerome Analysis Network-Breast dataset (SCAN-B)
G Villacampa, T Pascual, F Brasó-Maristany, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 9, 2011
PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel, and CMF versus a standard-dosed epirubicin-cyclophosphamide followed by paclitaxel with or without darbepoetin alfa in primary breast cancer--outcome on prognosis
M Untch, G von Minckwitz, G E Konecny, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 29, 2024
Early prediction of endocrine responsiveness in ER+/HER2-negative metastatic breast cancer (MBC): pilot study with <sup>18</sup>F-fluoroestradiol (<sup>18</sup>F-FES) CT/PET
A Gennari, E Brain, A De Censi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 16, 2023
Nab-paclitaxel weekly versus dose-dense solvent-based paclitaxel followed by dose-dense epirubicin plus cyclophosphamide in high-risk HR+/HER2- early breast cancer: results from the neoadjuvant part of the WSG-ADAPT-HR+/HER2- trial
O Gluz, S Kuemmel, U Nitz, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 10, 2011
PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel and CMF versus a standard-dosed epirubicin/cyclophosphamide followed by paclitaxel ± darbepoetin alfa in primary breast cancer--results at the time of surgery
M Untch, P A Fasching, G E Konecny, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 19, 2025
ESMO guidance on the use of Large Language Models in Clinical Practice (ELCAP)
E Y T Wong, L Verlingue, M Aldea, et al.
Page
of 15
Search research articles
Search
Showing results (111-120 of 148) with videos related to
Sort By:
Page
of 15
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 26, 2017
De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR- phase II trial: efficacy, safety, and predictive markers for 12 weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab ± weekly paclitaxel
U A Nitz, O Gluz, M Christgen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 6, 2024
A pooled analysis of trastuzumab deruxtecan in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer with brain metastases
F André, J Cortés, G Curigliano, et al.
ESMO Open
|
November 28, 2021
Prognostic relevance of the HER2 status of circulating tumor cells in metastatic breast cancer patients screened for participation in the DETECT study program
V Müller, M Banys-Paluchowski, T W P Friedl, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 23, 2020
ESO-ESMO 4th International Consensus Guidelines for Breast Cancer in Young Women (BCY4)
S Paluch-Shimon, F Cardoso, A H Partridge, et al.
ESMO Open
|
March 5, 2024
Prognostic value of HER2DX in early-stage HER2-positive breast cancer: a comprehensive analysis of 757 patients in the Sweden Cancerome Analysis Network-Breast dataset (SCAN-B)
G Villacampa, T Pascual, F Brasó-Maristany, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 9, 2011
PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel, and CMF versus a standard-dosed epirubicin-cyclophosphamide followed by paclitaxel with or without darbepoetin alfa in primary breast cancer--outcome on prognosis
M Untch, G von Minckwitz, G E Konecny, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 29, 2024
Early prediction of endocrine responsiveness in ER+/HER2-negative metastatic breast cancer (MBC): pilot study with <sup>18</sup>F-fluoroestradiol (<sup>18</sup>F-FES) CT/PET
A Gennari, E Brain, A De Censi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 16, 2023
Nab-paclitaxel weekly versus dose-dense solvent-based paclitaxel followed by dose-dense epirubicin plus cyclophosphamide in high-risk HR+/HER2- early breast cancer: results from the neoadjuvant part of the WSG-ADAPT-HR+/HER2- trial
O Gluz, S Kuemmel, U Nitz, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 10, 2011
PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel and CMF versus a standard-dosed epirubicin/cyclophosphamide followed by paclitaxel ± darbepoetin alfa in primary breast cancer--results at the time of surgery
M Untch, P A Fasching, G E Konecny, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 19, 2025
ESMO guidance on the use of Large Language Models in Clinical Practice (ELCAP)
E Y T Wong, L Verlingue, M Aldea, et al.
Page
of 15